Black Diamond Therapeutics (BDTX) EBIAT: 2018-2021
Historic EBIAT for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to -$25.9 million.
- Black Diamond Therapeutics' EBIAT fell 14.32% to -$25.9 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$113.9 million, marking a year-over-year decrease of 69.31%. This contributed to the annual value of -$125.6 million for FY2021, which is 86.75% down from last year.
- Per Black Diamond Therapeutics' latest filing, its EBIAT stood at -$25.9 million for Q4 2021, which was up 26.26% from -$35.1 million recorded in Q3 2021.
- In the past 5 years, Black Diamond Therapeutics' EBIAT ranged from a high of -$3.1 million in Q4 2018 and a low of -$35.1 million during Q3 2021.
- Moreover, its 3-year median value for EBIAT was -$14.6 million (2020), whereas its average is -$17.6 million.
- Data for Black Diamond Therapeutics' EBIAT shows a maximum YoY slumped of 222.08% (in 2019) over the last 5 years.
- Quarterly analysis of 4 years shows Black Diamond Therapeutics' EBIAT stood at -$3.1 million in 2018, then crashed by 222.08% to -$9.9 million in 2019, then tumbled by 129.12% to -$22.6 million in 2020, then declined by 14.32% to -$25.9 million in 2021.
- Its EBIAT was -$25.9 million in Q4 2021, compared to -$35.1 million in Q3 2021 and -$30.3 million in Q2 2021.